PHD2 mutation and congenital erythrocytosis with paraganglioma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19092153.
- Also identified by DOI 10.1056/NEJMoa0806277.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prolyl hydroxylase domain (PHD) proteins play a major role in regulating the hypoxia-inducible factor (HIF) that induces expression of genes involved in angiogenesis, erythropoiesis, and cell metabolism, proliferation, and survival. Germ-line mutations in the prolyl hydroxylase domain 2 gene (PHD2) have been reported in patients with familial erythrocytosis but not in association with tumors. We describe a patient with erythrocytosis and recurrent paraganglioma who carries a newly discovered PHD2 mutation. This mutation affects PHD2 function and stabilizes HIF-alpha proteins. In addition, we demonstrate loss of heterozygosity of PHD2 in the tumor, suggesting that PHD2 could be a tumor-suppressor gene.
Medical subject headings
- Germ-Line Mutation
- Loss of Heterozygosity
- Mediastinal Neoplasms
- Paraganglioma
- Polycythemia
- Procollagen-Proline Dioxygenase